Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean Marc Phelip

Showing results (101-110 of 118) with videos related to

Pageof 12
Sort By:
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|June 9, 2024
Relative dose intensity of first-line triplet chemotherapy in metastatic colorectal cancerJulien Hoba, Adrien Grancher, Vincent Hautefeuille, et al.
Swiss Medical Weekly|December 29, 2021
Local treatment in the setting of de novo metastatic rectal cancer: reappraisal of prognostic factorsNicolas Vial, Julien Langrand-Escure, Peng Diao, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 3, 2021
Pembrolizumab with Capox Bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: The FFCD 1703-POCHI trialClaire Gallois, Jean-François Emile, Stefano Kim, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 26, 2021
Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiologyPeter R Galle, Masatoshi Kudo, Josep M Llovet, et al.
European Journal of Cancer (Oxford, England : 1990)|July 5, 2022
Combination of CDX2 H-score quantitative analysis with CD3 AI-guided analysis identifies patients with a good prognosis only in stage III colon cancerValentin Derangère, Julie Lecuelle, Come Lepage, et al.
American Journal of Medical Genetics. Part A|September 20, 2015
Compound heterozygous PKHD1 variants cause a wide spectrum of ductal plate malformationsJean-Benoît Courcet, Anne Minello, Fabienne Prieur, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2026
Circulating tumor DNA dynamics and clinical outcomes in patients with advanced Colorectal Cancer treated with cetuximab-based induction and maintenance treatmentValérie Boige, Olivier Bouché, Claire Mulot, et al.
European Journal of Cancer (Oxford, England : 1990)|April 7, 2026
Corrigendum to "Combination of CDX2H-score quantitative analysis with CD3 AI-guided analysis identifies patients with a good prognosis only in stage III colon cancer" [In European Journal of Cancer, Volume 172, 2022, Pages 221-230, ISSN 0959-8049]Valentin Derangère, Julie Lecuelle, Come Lepage, et al.
JAMA Network Open|September 18, 2023
Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical TrialValérie Boige, Hélène Blons, Eric François, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|March 5, 2025
Bevacizumab-based chemotherapy adaptive to pharmacokinetic of bevacizumab in first-line treatment of patients with unresectable metastatic colorectal cancer: A double-blind, multicenter, randomized phase III trial study (PHARBEVACOL trial)Thierry Lecomte, Bruno Giraudeau, Jean-Marc Phelip, et al.
Pageof 12

Showing results (101-110 of 118) with videos related to

Sort By:
Pageof 12
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|June 9, 2024
Relative dose intensity of first-line triplet chemotherapy in metastatic colorectal cancerJulien Hoba, Adrien Grancher, Vincent Hautefeuille, et al.
Swiss Medical Weekly|December 29, 2021
Local treatment in the setting of de novo metastatic rectal cancer: reappraisal of prognostic factorsNicolas Vial, Julien Langrand-Escure, Peng Diao, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 3, 2021
Pembrolizumab with Capox Bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: The FFCD 1703-POCHI trialClaire Gallois, Jean-François Emile, Stefano Kim, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 26, 2021
Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiologyPeter R Galle, Masatoshi Kudo, Josep M Llovet, et al.
European Journal of Cancer (Oxford, England : 1990)|July 5, 2022
Combination of CDX2 H-score quantitative analysis with CD3 AI-guided analysis identifies patients with a good prognosis only in stage III colon cancerValentin Derangère, Julie Lecuelle, Come Lepage, et al.
American Journal of Medical Genetics. Part A|September 20, 2015
Compound heterozygous PKHD1 variants cause a wide spectrum of ductal plate malformationsJean-Benoît Courcet, Anne Minello, Fabienne Prieur, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2026
Circulating tumor DNA dynamics and clinical outcomes in patients with advanced Colorectal Cancer treated with cetuximab-based induction and maintenance treatmentValérie Boige, Olivier Bouché, Claire Mulot, et al.
European Journal of Cancer (Oxford, England : 1990)|April 7, 2026
Corrigendum to "Combination of CDX2H-score quantitative analysis with CD3 AI-guided analysis identifies patients with a good prognosis only in stage III colon cancer" [In European Journal of Cancer, Volume 172, 2022, Pages 221-230, ISSN 0959-8049]Valentin Derangère, Julie Lecuelle, Come Lepage, et al.
JAMA Network Open|September 18, 2023
Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical TrialValérie Boige, Hélène Blons, Eric François, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|March 5, 2025
Bevacizumab-based chemotherapy adaptive to pharmacokinetic of bevacizumab in first-line treatment of patients with unresectable metastatic colorectal cancer: A double-blind, multicenter, randomized phase III trial study (PHARBEVACOL trial)Thierry Lecomte, Bruno Giraudeau, Jean-Marc Phelip, et al.
Pageof 12